Overall, these observations suggest that oestrogen deprivation in combination with AEE788, or similar EGFR/HER2 inhibitors, may be superior for the treatment of both de novo and acquired ER+, HER2+ endocrine-resistant breast cancer and may also show potential mechanisms through which resistance to therapy may arise. Here, EGFR is linked to breast cancer.